From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Charleston event is provided here. The purpose of...
Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Charleston).mp4
Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble NKG2D ligands are associated with poor clinical response to PD1/PD-L1 blockade therapy...
Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity. The authors...
LUNGevity's Patient Education Series offers several comprehensive booklets and brochures written and illustrated clearly to help patients understand their diagnosis and treatment options as well as the support services available through LUNGevity. These materials will help you learn about lung...
Oncolytic viral (OV) therapy has become a promising cancer immunotherapy because of its potential effectiveness, specificity and long-lasting immunity. In this article the authors describe and characterize a novel cancer immunotherapy combining Sindbis virus (SV) vectors and the agonistic...
Edited by: Lisa H. Butterfield, PhD, SITC Immediate Past President Howard L. Kaufman, MD, FACS, Past SITC President Francesco M. Marincola, MD, Past SITC President Cancer Immunotherapy Principles and Practice , from the Society for Immunotherapy of Cancer (SITC) , is an...
Edited By: Marc S. Ernstoff, MD – Roswell Park Comprehensive Cancer Center Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center Caroline Robert, MD, PhD – Institut Gustave Roussy Adi Diab, MD – The University of Texas MD Anderson Cancer Center Peter Hersey, MD, PhD – ...
The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies is raising questions on their potential immunogenicity and effects on treatment. In this review, the authors outline the mechanisms of action (MOA) of approved, antibody-based IMD agents, potentially related to...
The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Patient derived colorectal cancer organoids (PDOs) may...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us